2024

• Bawden, E., Wagner, T., Schröder, J., Effern, M., Hinze, D., Newland, L., Attrill, G., Lee, A., Engel, S., Freestone, D., Ferguson, A., Edwards, J., Ferguson, P., Scolyer, R., Wilmott, J., Palendira, M., et al (2024). CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses. Science Immunology, 9(91). [More Information]
• Versluis, J., Blankenstein, S., Dimitriadis, P., Wilmott, J., Elens, R., Blokx, W., Menzies, A., Scolyer, R., Long, G., van Akkooi, A., et al (2024). Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. Journal for ImmunoTherapy of Cancer, 12(4), e008125. [More Information]
• Bai, X., Attrill, G., Gide, T., Ferguson, P., Nahar, K., Shang, P., Vergara Correa, I., Palendira, M., Esteves Domingues Pires da Silva, I., Carlino, M., Menzies, A., Long, G., Scolyer, R., Wilmott, J., Quek, C. (2024). Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma. Nature Communications, 15(1), 3014. [More Information]

2023

• Adegoke, N., Gide, T., Mao, Y., Quek, C., Patrick, E., Carlino, M., Lo, S., Menzies, A., Esteves Domingues Pires da Silva, I., Vergara Correa, I., Long, G., Scolyer, R., Wilmott, J. (2023). Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. Journal for ImmunoTherapy of Cancer, 11(10). [More Information]
• Wilmott, J., Tawbi, H., Engh, J., Amankulor, N., Shivalingam, B., Banerjee, H., Vergara Correa, I., Lee, H., Johansson, P., Ferguson, P., Scolyer, R., Long, G., et al (2023). Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clinical Cancer Research, 29(3), 521-531. [More Information]
• Mao, Y., Gide, T., Adegoke, N., Quek, C., Maher, N., Potter, A., Patrick, E., Saw, R., Thompson, J., Spillane, A., Shannon, K., Carlino, M., Lo, S., Menzies, A., Da Silva, I., Long, G., Scolyer, R., Wilmott, J. (2023). Cross‑platform comparison of immune signatures in immunotherapy‑treated patients with advanced melanoma using a rank‑based scoring approach. Journal of Translational Medicine, 21(Green Open Access), Article 257-16 pages. [More Information]
• Vergara Correa, I., Aivazian, K., Carlino, M., Guminski, A., Maher, N., Shannon, K., Ch'ng, S., Saw, R., Long, G., Wilmott, J., Scolyer, R. (2023). Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets. Modern Pathology, 36(4), 100099. [More Information]
• Chakraborty, A., Perez, M., Carroll, J., Antonopoulos, A., Dell, A., Ortega, L., Mohammed, N., Wells, M., Staudinger, C., Griswold, A., Wilmott, J., Thompson, J., Scolyer, R., et al (2023). Hypoxia Controls the Glycome Signature and Galectin-8–Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma. Journal of Investigative Dermatology, 143(3), 456-469.e8. [More Information]
• Orlow, I., Sadeghi, K., Edmiston, S., Kenney, J., Lezcano, C., Wilmott, J., Cust, A., Scolyer, R., Mann, G., Lee, T., Burke, H., Jakrot, V., Shang, P., Ferguson, P., et al (2023). InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PloS One, 18(2023-04-04 00:00:00). [More Information]
• Lee, H., Ferguson, A., Quek, C., Vergara Correa, I., Esteves Domingues Pires da Silva, I., Allen, R., Gide, T., Conway, J., Koufariotis, L., Hayward, N., Carlino, M., Menzies, A., Saw, R., Shklovskaya, E., Rizos, H., Lo, S., Scolyer, R., Long, G., Palendira, M., Wilmott, J., et al (2023). Intratumoral CD16þ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy. Clinical Cancer Research, 29(13), 2513-2524. [More Information]
• Gide, T., Paver, E., Yaseen, Z., Maher, N., Adegoke, N., Menzies, A., Esteves Domingues Pires da Silva, I., Wilmott, J., Long, G., Scolyer, R. (2023). Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. OncoImmunology, 12(1), 2261248. [More Information]
• El Sharouni, M., Rawson, R., Potter, A., Paver, E., Wilmott, J., Witkamp, A., Sigurdsson, V., van Diest, P., Scolyer, R., Thompson, J., Lo, S., et al (2023). Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. Journal Of The American Academy Of Dermatology, 88(3), 609-616. [More Information]
• Shteinman, E., Vergara Correa, I., Rawson, R., Lo, S., Maeda, N., Koyama, K., Esteves Domingues Pires da Silva, I., Long, G., Scolyer, R., Wilmott, J., Menzies, A. (2023). Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma. Pathology, 55(5), 629-636. [More Information]
• Hahn, A., Quek, C., Zang, Y., Spencer, C., Menzies, A., Daniel, C., Hudgens, C., Nowicki, T., Haydu, L., Khan, M., Thompson, J., Long, G., Scolyer, R., Wilmott, J., Gide, T., et al (2023). Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clinical Cancer Research, 29(1), 154-164. [More Information]
• Sawyer, A., Patrick, E., Edwards, J., Wilmott, J., Fielder, T., Yang, Q., Barber, D., Ernst, J., Britton, W., Palendira, M., Feng, C., et al (2023). Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis. The Journal of Experimental Medicine, 220(6), e20221392. [More Information]
• Paver, E., Aivazian, K., Maclean, F., Long, G., Spillane, A., Wilmott, J., Scolyer, R. (2023). Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. Pathology, 55(4), 555-560. [More Information]

2022

• Weiss, J., Hunter, M., Cruz, N., Baggiolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N., Wilmott, J., Thompson, J., Long, G., Mann, G., Scolyer, R., et al (2022). Anatomic position determines oncogenic specificity in melanoma. Nature, 604(7905), 354-361. [More Information]
• Shteinman, E., Wilmott, J., Esteves Domingues Pires da Silva, I., Long, G., Scolyer, R., Vergara Correa, I. (2022). Causes, consequences and clinical significance of aneuploidy across melanoma subtypes. Frontiers in Oncology, 12. [More Information]
• Wang, M., Zadeh, S., Pizzolla, A., Thia, K., Gyorki, D., McArthur, G., Scolyer, R., Long, G., Wilmott, J., Andrews, M., et al (2022). Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. Journal for ImmunoTherapy of Cancer, 10(4), e004095. [More Information]
• Newell, F., Johansson, P., Wilmott, J., Nones, K., Lakis, V., Pritchard, A., Lo, S., Rawson, R., Kazakoff, S., Colebatch, A., Ferguson, P., Vergara Correa, I., Long, G., Nieweg, O., Shivalingam, B., Stretch, J., Spillane, A., Saw, R., Shannon, K., Thompson, J., et al (2022). Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discovery, 12(12), 2856-2879. [More Information]
• Colebatch, A., Adhikari, C., Diefenbach, R., Rawson, R., Ferguson, P., Rizos, H., Long, G., McCarthy, S., Thompson, J., Wilmott, J., Scolyer, R. (2022). Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi. American Journal of Surgical Pathology, 46(8), 1048-1059. [More Information]
• Attrill, G., Lee, H., Tasker, A., Adegoke, N., Ferguson, A., Esteves Domingues Pires da Silva, I., Saw, R., Thompson, J., Palendira, M., Long, G., Ferguson, P., Scolyer, R., Wilmott, J. (2022). Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. Frontiers in Immunology, 13. [More Information]
• Rawson, R., Shteinman, E., Ansar, S., Vergara Correa, I., Thompson, J., Long, G., Scolyer, R., Wilmott, J. (2022). Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. Pathology, 54(7), 863-873. [More Information]
• Simpson, R., Shanahan, E., Batten, M., Reijers, I., Read, M., Da Silva, I., Versluis, J., Ribeiro, R., Angelatos, A., Tan, J., Adhikari, C., Menzies, A., Saw, R., Gonzalez, M., Shannon, K., Spillane, A., Velickovic, R., Macia, L., Holmes, A., Wilmott, J., Scolyer, R., Long, G., et al (2022). Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nature Medicine, 28(11), 2344-2352. [More Information]
• Nahar, K., Marsh-Wakefield, F., Rawson, R., Gide, T., Ferguson, A., Allen, R., Quek, C., Esteves Domingues Pires da Silva, I., Tattersal, S., Kiely, C., Carlino, M., McCaughan, G., Wilmott, J., Scolyer, R., Long, G., Menzies, A., Palendira, M., et al (2022). Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight, 7(21). [More Information]
• Colebatch, A., Paver, E., Vergara Correa, I., Thompson, J., Long, G., Wilmott, J., Scolyer, R. (2022). Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology, 54(5), 533-540. [More Information]
• Marsland, M., Dowdell, A., Jiang, C., Wilmott, J., Scolyer, R., Zhang, X., Hondermarck, H., Faulkner, S. (2022). Expression of NGF/proNGF and Their Receptors TrkA, p75NTR and Sortilin in Melanoma. International Journal of Molecular Sciences, 23(8), 4260. [More Information]
• Vergara Correa, I., Wilmott, J., Long, G., Scolyer, R. (2022). Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Experimental Dermatology, 31(1), 13-30. [More Information]
• Attrill, G., Owen, C., Ahmed, T., Vergara Correa, I., Colebatch, A., Conway, J., Nahar, K., Thompson, J., Esteves Domingues Pires da Silva, I., Carlino, M., Menzies, A., Lo, S., Palendira, M., Scolyer, R., Long, G., Wilmott, J. (2022). Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer, 10(6). [More Information]
• Luo, L., Shen, R., Arora, A., Orlow, I., Busam, K., Lezcano, C., Lee, T., Hernando, E., Gorlov, I., Amos, C., Cust, A., Wilmott, J., Scolyer, R., et al (2022). Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. Pigment Cell & Melanoma Research, 35(6), 605-612. [More Information]
• Newell, F., Esteves Domingues Pires da Silva, I., Johansson, P., Menzies, A., Wilmott, J., Addala, V., Carlino, M., Rizos, H., Nones, K., Edwards, J., Ferguson, P., Thompson, J., Spillane, A., Saw, R., Shannon, K., Mann, G., Scolyer, R., Long, G., et al (2022). Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 40(1), 88-1.02E+09. [More Information]
• Star, P., Jackett, L., Cheung, K., Wilmott, J., Ho, G., Smith, A., Long, G., Scolyer, R., Martin, L. (2022). Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. Dermatologic therapy, 35(6). [More Information]
• Aung, T., Shafi, S., Wilmott, J., Nourmohammadi, S., Vathiotis, I., Gavrielatou, N., Fernandez, A., Yaghoobi, V., Sinnberg, T., Amaral, T., Thompson, J., Scolyer, R., et al (2022). Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine, 82. [More Information]
• Conway, J., Braden, J., Wilmott, J., Scolyer, R., Long, G., Esteves Domingues Pires da Silva, I. (2022). The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Frontiers in Immunology, 13. [More Information]
• Conway, J., Rawson, R., Lo, S., Ahmed, T., Vergara Correa, I., Gide, T., Attrill, G., Carlino, M., Saw, R., Thompson, J., Spillane, A., Shannon, K., Shivalingam, B., Menzies, A., Wilmott, J., Long, G., Scolyer, R., Esteves Domingues Pires da Silva, I. (2022). Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. Journal for ImmunoTherapy of Cancer, 10(9). [More Information]

2021

• Haas, L., Elewaut, A., Gerard, C., Umkehrer, C., Leiendecker, L., Pedersen, M., Krecioch, I., Hoffmann, D., Novatchkova, M., Kuttke, M., Da Silva, I., Scolyer, R., Long, G., Wilmott, J., et al (2021). Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2(7), 693-708. [More Information]
• Gide, T., Esteves Domingues Pires da Silva, I., Quek, C., Ferguson, P., Batten, M., Shang, P., Ahmed, T., Menzies, A., Carlino, M., Saw, R., Thompson, J., Scolyer, R., Long, G., Wilmott, J. (2021). Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 13(13), 3186-1-3186-16. [More Information]
• Wu, S., Roden, D., Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A., Chan, C., Junankar, S., Hui, M., Millar, E., Horvath, L., Wilmott, J., Quek, C., Long, G., Scolyer, R., et al (2021). Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 13(1), 81. [More Information]
• Robertson, S., Orme, L., Teixeira, R., Shamassi, M., Newell, F., Patch, A., Yeh, I., Gard, G., Wilmott, J., Jackett, L., Scolyer, R., et al (2021). Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. JAMA Dermatology, 157(7), 836-841. [More Information]
• Kelly, G., Al-Ejeh, F., McCuaig, R., Casciello, F., Kamal, N., Ferguson, B., Pritchard, A., Ali, S., Da Silva, I., Wilmott, J., Long, G., Scolyer, R., et al (2021). G9a inhibition enhances checkpoint inhibitor blockade response in Melanoma. Clinical Cancer Research, 27(9), 2624-2635. [More Information]
• Gherardin, N., Waldeck, K., Caneborg, A., Martelotto, L., Balachander, S., Zethoven, M., Petrone, P., Pattison, A., Wilmott, J., Quiñones-Parra, S., Shannon, K., Hong, A., Ferguson, P., Jakrot, V., Gill, A., Scolyer, R., et al (2021). gd T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival. Cancer Immunology Research, 9(6), 612-623. [More Information]
• Quek, C., Bai, X., Long, G., Scolyer, R., Wilmott, J. (2021). High-dimensional single-cell transcriptomics in melanoma and cancer immunotherapy. Genes, 12(10), 1629-1-1629-21. [More Information]
• Gallagher, S., Bailey, T., Rawson, R., Mahar, A., Thompson, J., Long, G., Wilmott, J., Scolyer, R. (2021). Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. Pathology, 53(7), 830-835. [More Information]
• Rawson, R., Wilmott, J., Scolyer, R. (2021). Mucosal Melanoma: A Review Emphasizing the Molecular Landscape and Implications for Diagnosis and Management. Surgical Pathology Clinics, 14(2), 293-307. [More Information]
• Rawson, R., Adhikari, C., Bierman, C., Lo, S., Shklovskaya, E., Rozeman, E., Menzies, A., van Akkooi, A., Shannon, K., Gonzalez, M., Guminski, A., Stretch, J., Nieweg, O., Ch'ng, S., Rizos, H., Saw, R., Spillane, A., Wilmott, J., Long, G., Scolyer, R., et al (2021). Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 32(6), 766-777. [More Information]
• Lee, H., Da Silva, I., Palendira, M., Scolyer, R., Long, G., Wilmott, J. (2021). Targeting nk cells to enhance melanoma response to immunotherapies. Cancers, 13(6), 1-30. [More Information]
• Giblin, W., Mostafa, A., Lee, H., Zhang, L., Sajjakulnukit, P., Trefely, S., Varner, E., Iyer, S., Wilmott, J., Peter Soyer, H., Scolyer, R., et al (2021). The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. Journal of Clinical Investigation, 131(12), e138926. [More Information]
• Attrill, G., Ferguson, P., Palendira, M., Long, G., Wilmott, J., Scolyer, R. (2021). The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell & Melanoma Research, 34(3), 529-549. [More Information]
• Garg, M., Couturier, D., Nsengimana, J., Fonseca, N., Wongchenko, M., Yan, Y., Lauss, M., Jönsson, G., Newton-Bishop, J., Parkinson, C., Vergara Correa, I., Lo, S., Wilmott, J., Thompson, J., Long, G., Scolyer, R., et al (2021). Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 12(1), 1137. [More Information]

2020

• Braun, M., Aguilera, A., Sundarrajan, A., Corvino, D., Stannard, K., Krumeich, S., Das, I., Lima, L., Meza Guzman, L., Li, K., Wilmott, J., Long, G., Scolyer, R., et al (2020). CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8(+) T Cells. Immunity, 53(4), 805-823.e15. [More Information]
• Gide, T., Da Silva, I., Quek, C., Ahmed, T., Menzies, A., Carlino, M., Saw, R., Thompson, J., Batten, M., Long, G., Scolyer, R., Wilmott, J. (2020). Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. OncoImmunology, 9(1), 1659093. [More Information]
• Tetzlaff, M., Adhikari, C., Lo, S., Rawson, R., Amaria, R., Menzies, A., Wilmott, J., Ferguson, P., Ross, M., Spillane, A., Saw, R., Long, G., Scolyer, R., et al (2020). Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 31(11), 1569-1579. [More Information]
• Ziemys, A., Kim, M., Menzies, A., Wilmott, J., Long, G., Scolyer, R., Kwong, L., Holder, A., Boland, G. (2020). Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Frontiers in Oncology, 10, 1-9. [More Information]
• House, I., Savas, P., Lai, J., Chen, A., Oliver, A., Teo, Z., Todd, K., Henderson, M., Giuffrida, L., Petley, E., Gide, T., Quek, C., Scolyer, R., Long, G., Wilmott, J., et al (2020). Macrophage derived CXCL9 and CXCL10 are required for anti-tumor immune responses following immune checkpoint blockade. Clinical Cancer Research, 26(2), 487-504. [More Information]
• Pruessmann, W., Rytlewski, J., Wilmott, J., Mihm Jr, M., Attrill, G., Dyring-Andersen, B., Fields, P., Zhan, Q., Colebatch, A., Ferguson, P., Thompson, J., Scolyer, R., et al (2020). Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 1(2), 197-209. [More Information]
• Jackett, L., Colebatch, A., Rawson, R., Ferguson, P., Thompson, J., McCarthy, S., Wilmott, J., Scolyer, R. (2020). Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. The American Journal of Surgical Pathology, 44(3), 357-367. [More Information]
• Barnhill, R., van Dam, P., Vermeulen, P., Champenois, G., Nicolas, A., Rawson, R., Wilmott, J., Thompson, J., Long, G., Cassoux, N., Scolyer, R., et al (2020). Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. The Journal of Pathology: Clinical Research, 6(3), 195-206. [More Information]
• Li, C., Prokopec, S., Sun, R., Yousif, F., Schmitz, N., Al-Shahrour, F., Atwal, G., Bailey, P., Biankin, A., Burke, H., et al (2020). Sex differences in oncogenic mutational processes. Nature Communications, 11(1), 4330. [More Information]
• McKelvey, K., Hudson, A., Kumar, R., Wilmott, J., Attrill, G., Long, G., Scolyer, R., Clarke, S., Wheeler, H., Diakos, C., Howell, V. (2020). Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. PloS One, 15(4), e0226444. [More Information]
• Ipenburg, N., Lo, S., Vilain, R., Holtkamp, L., Wilmott, J., Nieweg, O., Thompson, J., Scolyer, R. (2020). The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. Journal Of The American Academy Of Dermatology, 82(4), 910-919. [More Information]
• Lee, J., Shklovskaya, E., Lim, S., Carlino, M., Menzies, A., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J., Strbenac, D., Saw, R., Thompson, J., Wilmott, J., Scolyer, R., Long, G., et al (2020). Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 11(1), 1-12. [More Information]
• Lepletier, A., Madore, J., O'Donnell, J., Johnston, R., Li, X., McDonald, E., Ahern, E., Kuchel, A., Eastgate, M., Pearson, S., Wilmott, J., Menzies, A., Long, G., Scolyer, R., et al (2020). Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 26(14), 3671-3681. [More Information]
• Edwards, J., Ferguson, P., Lo, S., Da Silva, I., Colebatch, A., Lee, H., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, M., Wilmott, J., et al (2020). Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas. Cancer Immunology Research, 8(11), 1346-1353. [More Information]
• Johansson, P., Brooks, K., Newell, F., Palmer, J., Wilmott, J., Pritchard, A., Broit, N., Wood, S., Carlino, M., Leonard, C., Rizos, H., Long, G., Mann, G., Scolyer, R., et al (2020). Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 11(1), 1-8. [More Information]
• Newell, F., Wilmott, J., Johansson, P., Nones, K., Addala, V., Mukhopadhyay, P., Broit, N., Amato, C., Van Gulick, R., Kazakoff, S., Saw, R., Spillane, A., Stretch, J., Rawson, R., Ferguson, P., Dodds, T., Thompson, J., Long, G., et al (2020). Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 11(1), 1-14. [More Information]

2019

• Gide, T., Quek, C., Menzies, A., Tasker, A., Shang, P., Holst, J., Madore, J., Lim, S., Wongchenko, M., Lo, S., Carlino, M., Guminski, A., Saw, R., Pang, A., McGuire, H., Palendira, M., Thompson, J., Rizos, H., Da Silva, I., Batten, M., Scolyer, R., Long, G., Wilmott, J., et al (2019). Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 35(2), 238-255.e6. [More Information]
• Da Silva, I., Wang, K., Wilmott, J., Holst, J., Carlino, M., Park, J., Quek, C., Wongchenko, M., Yan, Y., Mann, G., Rai, R., Kefford, R., Rizos, H., Scolyer, R., Yang, J., Long, G., Menzies, A., et al (2019). Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. Clinical Cancer Research, 25(4), 1272-1279. [More Information]
• Lee, H., Quek, C., Da Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S., Gide, T., Shang, P., Attrill, G., Madore, J., Edwards, J., Carlino, M., Guminski, A., Saw, R., Thompson, J., Ferguson, P., Palendira, M., Menzies, A., Long, G., Scolyer, R., Wilmott, J. (2019). Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology, 8(2), e1537581-1-e1537581-10. [More Information]
• Gide, T., Allanson, B., Menzies, A., Ferguson, P., Madore, J., Saw, R., Thompson, J., Long, G., Wilmott, J., Scolyer, R. (2019). Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment. Histopathology, 74(6), 817-828. [More Information]
• Ding, L., Sun, Q., Edwards, J., Fernandez, L., Ran, X., Zhou, S., Scolyer, R., Wilmott, J., Thompson, J., Doan, N., et al (2019). LNK suppresses interferon signaling in melanoma. Nature Communications, 10(1), 1-13. [More Information]
• Colebatch, A., Ferguson, P., Newell, F., Kazakoff, S., Witkowski, T., Dobrovic, A., Johansson, P., Saw, R., Stretch, J., McArthur, G., Long, G., Thompson, J., Mann, G., Scolyer, R., Wilmott, J., et al (2019). Molecular Genomic Profiling of Melanocytic Nevi. Journal of Investigative Dermatology, 139(8), 1762-1768. [More Information]
• Long, G., Saw, R., Lo, S., Nieweg, O., Shannon, K., Gonzales, M., Guminski, A., Lee, J., Lee, H., Ferguson, P., Rawson, R., Wilmott, J., Thompson, J., Kefford, R., Ch'ng, S., Stretch, J., Rizos, H., Spillane, A., Scolyer, R., Menzies, A., et al (2019). Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. The Lancet Oncology, 20(7), 961-971. [More Information]
• Edwards, J., Batten, M., Ferguson, A., Palendira, M., Wilmott, J., Long, G., Scolyer, R. (2019). Novel Immune Targets in Melanoma-Response. Clinical Cancer Research, 25(17), 5424-5425. [More Information]
• Edwards, J., Tasker, A., Da Silva, I., Quek, C., Batten, M., Ferguson, A., Allen, R., Allanson, B., Saw, R., Thompson, J., Menzies, A., Palendira, M., Wilmott, J., Long, G., Scolyer, R. (2019). Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma: implications for clinical trials. Clinical Cancer Research, 25(11), 3247-3258. [More Information]
• Dodds, T., Wilmott, J., Jackett, L., Lo, S., Long, G., Thompson, J., Scolyer, R. (2019). Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 51(1), 39-45. [More Information]
• Guo, D., Lui, G., Lai, S., Wilmott, J., Tikoo, S., Jackett, L., Quek, C., Brown, D., Sharp, D., Kwan, R., van Geldermalsen, M., Holst, J., Thompson, J., Mann, G., Scolyer, R., Weninger, W., Haass, N., Beaumont, K., et al (2019). RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes. International Journal of Cancer, 144(12), 3070-3085. [More Information]
• Quek, C., Rawson, R., Ferguson, P., Shang, P., Da Silva, I., Saw, R., Shannon, K., Thompson, J., Hayward, N., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2019). Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 10(9), 930-941. [More Information]
• Zhao, X., Little, P., Hoyle, A., Pegna, G., Hayward, M., Ivanova, A., Parker, J., Marron, D., Soloway, M., Jo, H., Wilmott, J., Quek, C., Thompson, J., Mann, G., et al (2019). The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 8, 1-14. [More Information]
• Park, S., Buzzai, A., Rautela, J., Hor, J., Hochheiser, K., Effern, M., McBain, N., Wagner, T., Edwards, J., McConville, R., Wilmott, J., Scolyer, R., Palendira, M., et al (2019). Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin. Nature, 565(7739), 366-371. [More Information]
• Wilmott, J., Johansson, P., Newell, F., Waddell, N., Ferguson, P., Quek, C., Patch, A., Nones, K., Shang, P., Pritchard, A., Saw, R., Spillane, A., Stretch, J., Shannon, K., Kefford, R., Menzies, A., Long, G., Thompson, J., Mann, G., Scolyer, R., et al (2019). Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 144(5), 1049-1060. [More Information]
• Newell, F., Kong, Y., Wilmott, J., Johansson, P., Ferguson, P., Cui, C., Li, Z., Kazakoff, S., Burke, H., Dodds, T., Tembe, V., Shang, P., Lo, S., Rawson, R., Long, G., Spillane, A., Shannon, K., Thompson, J., Saw, R., Mann, G., Scolyer, R., et al (2019). Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 10(1), 1-15. [More Information]

2018

• Salomon, M., Orozco, J., Wilmott, J., Hothi, P., Manughian-Peter, A., Cobbs, C., Scolyer, R., Hoon, D., Marzese, D. (2018). Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. Scientific Data, 5, 1-8. [More Information]
• Edwards, J., Wilmott, J., Madore, J., Gide, T., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Weninger, W., Britton, W., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, M., et al (2018). CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clinical Cancer Research, 24(13), 3036-3045. [More Information]
• Long, G., Atkinson, V., Lo, S., Sandhu, S., Guminski, A., Brown, M., Wilmott, J., Edwards, J., Gonzalez, M., Scolyer, R., Menzies, A., et al (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672-681. [More Information]
• Lai, K., Matthews, S., Wilmott, J., Killingsworth, M., Yong, J., Caixeiro, N., Wykes, J., Samakeh, A., Forstner, D., Lee, M., Hong, A., Lee, C., et al (2018). Differences in LC3B expression and prognostic implications in oropharyngeal and oral cavity squamous cell carcinoma patients. BMC Cancer, 18(1), 1-12. [More Information]
• Orozco, J., Knijnenburg, T., Manughian-Peter, A., Salomon, M., Barkhoudarian, G., Jalas, J., Wilmott, J., Hothi, P., Wang, X., Takasumi, Y., Buckland, M., Thompson, J., Long, G., Scolyer, R., et al (2018). Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications, 9(1), 1-14. [More Information]
• Gallagher, S., Gunatilake, D., Beaumont, K., Sharp, D., Tiffen, J., Heinemann, A., Weninger, W., Haass, N., Wilmott, J., Madore, J., Ferguson, P., Rizos, H., Hersey, P. (2018). HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 142(9), 1926-1937. [More Information]
• Cai, H., Cho, E., Li, Y., Sockler, J., Parish, C., Chong, B., Edwards, J., Dodds, T., Ferguson, P., Wilmott, J., Scolyer, R., Halliday, G., et al (2018). Melanoma protective antitumor immunity activated by catalytic DNA. Oncogene, 37(37), 5115-5126. [More Information]
• Gide, T., Wilmott, J., Scolyer, R., Long, G. (2018). Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clinical Cancer Research, 24(6), 1260-1270. [More Information]
• Krisp, C., Parker, R., Pascovici, D., Hayward, N., Wilmott, J., Thompson, J., Mann, G., Long, G., Scolyer, R., Molloy, M. (2018). Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. British Journal of Cancer, 119(6), 713-723. [More Information]
• Lee, M., Teber, E., Holmes, O., Nones, K., Patch, A., Dagg, R., Lau, L., Lee, J., Napier, C., Arthur, J., Hayward, N., Mann, G., Scolyer, R., Wilmott, J., Reddel, R., Pickett, H., et al (2018). Telomere sequence content can be used to determine ALT activity in tumours. Nucleic Acids Research, 46, 4903-4918. [More Information]

2017

• Wilmott, J., Hayward, N., Mann, G., Scolyer, R. (2017). Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. Melanoma Management, 4(3), 147-149. [More Information]
• Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
• Johansson, P., Pritchard, A., Patch, A., Wilmott, J., Pearson, J., Waddell, N., Scolyer, R., Mann, G., Hayward, N. (2017). Mutation load in melanoma is affected by MC1R genotype. Pigment Cell & Melanoma Research, 30(2), 255-258. [More Information]
• Kakavand, H., Jackett, L., Menzies, A., Gide, T., Carlino, M., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2017). Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 30(12), 1666-1676. [More Information]
• Kakavand, H., Rawson, R., Pupo, G., Yang, J., Menzies, A., Carlino, M., Kefford, R., Howle, J., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R., et al (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research, 23(20), 6054-6061. [More Information]
• Holtkamp, L., Wang, S., Wilmott, J., Madore, J., Vilain, R., Thompson, J., Nieweg, O., Scolyer, R. (2017). Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 01 mm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 24(Suppl3), 660. [More Information]
• Wang, J., Liu, G., Wilmott, J., La, T., Feng, Y., Yari, H., Yan, X., Thorne, R., Scolyer, R., Zhang, X., et al (2017). Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress. Cancer Research, 77(22), 6226-6239. [More Information]
• Wilmott, J., Rizos, H., Scolyer, R., Long, G. (2017). The "tricky business" of identifying mechanisms of resistance to anti-PD-1. Clinical Cancer Research, 23(12), 2921-2923. [More Information]
• Rawson, R., Johansson, P., Hayward, N., Waddell, N., Patch, A., Lo, S., Pearson, J., Thompson, J., Mann, G., Scolyer, R., Wilmott, J. (2017). Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 97(2), 130-145. [More Information]
• Hayward, N., Wilmott, J., Waddell, N., Johansson, P., Field, M., Nones, K., Patch, A., Kakavand, H., Alexandrov, L., Burke, H., Jakrot, V., Tembe, V., Pupo, G., De Paoli-Iseppi, R., Vilain, R., Shang, P., Lau, L., Dagg, R., Schramm, S., Pickett, H., Yang, J., Stretch, J., Kefford, R., Hersey, P., Long, G., Spillane, A., Saw, R., Thompson, J., Scolyer, R., Mann, G., et al (2017). Whole-genome landscapes of major melanoma subtypes. Nature, 545(7653), 175-180. [More Information]

2016

• Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 69(4), 680-686. [More Information]
• De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
• Fox, C., Lambie, D., Wilmott, J., Pinder, A., Pavey, S., Le Cao, K., Akalin, T., Karaarslan, I., Ozdemir, F., Scolyer, R., et al (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell & Melanoma Research, 29(4), 444-452. [More Information]
• Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
• Bosisio, F., Wilmott, J., Volders, N., Mercier, M., Wouters, J., Stas, M., Blokx, W., Massi, D., Thompson, J., Scolyer, R., et al (2016). Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 29(4), 347-358. [More Information]
• Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
• Kakavand, H., Wilmott, J., Long, G., Scolyer, R. (2016). Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 48(2), 194-202. [More Information]
• Van Kempen, L., Redpath, M., Elchebly, M., Klein, K., Papadakis, A., Wilmott, J., Scolyer, R., Edqvist, P., Pontén, F., Schadendorf, D., et al (2016). The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 8(369), 1-13. [More Information]

2015

• Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
• Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521. [More Information]
• Holtkamp, L., Wang, S., Wilmott, J., Madore, J., Vilain, R., Thompson, J., Nieweg, O., Scolyer, R. (2015). Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0,1mm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 22(9), 2972-2977. [More Information]
• Kiyohara, E., Donovan, N., Takeshima, L., Huang, S., Wilmott, J., Scolyer, R., Jones, P., Somers, E., O’Shannessy, D., Hoon, D. (2015). Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 8(2), 111-118. [More Information]
• Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
• Chi, M., Guo, S., Wilmott, J., Guo, X., Yan, X., Wang, C., Liu, X., Jin, L., Tseng, H., Liu, T., Scolyer, R., et al (2015). INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 6(37), 39891-39907. [More Information]
• Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
• Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
• Sanborn, J., Chung, J., Purdom, E., Wang, N., Kakavand, H., Wilmott, J., Butler, T., Thompson, J., Mann, G., Haydu, L., Saw, R., Scolyer, R., et al (2015). Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 112(35), 10995-11000. [More Information]
• Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J., Gartner, J., Di Pizio, A., Winograd-Katz, S., Mann, G., Scolyer, R., et al (2015). Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47(12), 1408-1410. [More Information]
• Liu, X., Lai, F., Yan, X., Jiang, C., Guo, S., Wang, C., Croft, A., Tseng, H., Wilmott, J., Scolyer, R., et al (2015). RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 75(8), 1736-1748. [More Information]
• Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
• Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]
• Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]
• Wong, S., Waldeck, K., Vergara, I., Schroder, J., Madore, J., Wilmott, J., Colebatch, A., De Paoli-Iseppi, R., Li, J., Lupat, R., Hruby, G., Mann, G., Thompson, J., Scolyer, R., Gill, A., et al (2015). UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 75(24), 5228-5234. [More Information]

2014

• Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell & Melanoma Research, 25(7), 696-697. [More Information]
• Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
• Marzese, D., Scolyer, R., Roqué, M., Vargas-Roig, L., Huynh, J., Wilmott, J., Murali, R., Buckland, M., Barkhoudarian, G., Thompson, J., et al (2014). DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 16(11), 1499-1509. [More Information]
• Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. Journal of Immunology, 192(5), 2505-2513. [More Information]
• Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
• Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
• Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
• Liu, Y., Lai, F., Wilmott, J., Yan, X., Liu, X., Luan, Q., Guo, S., Jiang, C., Tseng, H., Scolyer, R., et al (2014). Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 5(22), 11237-11251. [More Information]
• Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33(39), 4756-4766. [More Information]
• Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139. [More Information]

2013

• Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
• Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
• Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
• Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
• Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]

2012

• Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
• Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
• Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
• Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
• Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
• Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]

2011

• Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 15840-15845. [More Information]
• Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]

2009

• Busam, K., Murali, R., Pulitzer, M., McCarthy, S., Thompson, J., Shaw, H., Brady, M., Coit, D., Dusza, S., Wilmott, J., Scolyer, R., et al (2009). Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 33(9), 1386-1395. [More Information]
• Shingde, M., Buckland,, M., Busam, K., McCarthy, S., Wilmott, J., Thompson, J., Scolyer, R. (2009). Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 62(10), 915-919. [More Information]
• Howman-Giles, R., Shaw, H., Scolyer, R., Murali, R., Wilmott, J., McCarthy, S., Uren, R., Thompson, J. (2009). Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 17(1), 138-143. [More Information]

2008

• Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.